GVK Biosciences

Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica

If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica

Patients are telling the truth — just not to you

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.

Cuttsy + Cuttsy

FDA approves Priovant’s Lisraya for dermatomyositis

This is the first oral drug treatment for this rare disease in adults

AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer

The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression

Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA

The 2026-2027 vaccine targets the XFG variant to more closely match current variants

FDA grants Fast Track status for peanut allergy immunotherapy

The treatment uses peptides designed to retrain the immune system to tolerate peanuts

Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer

More than 186,000 men are diagnosed each year with mHSPC globally

EMA recommends granting marketing authorisation approval for Nezglyal

The treatment is for cerebral adrenoleukodystrophy, a rare neurodegenerative disease

AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma

Asthma affects over 360 million people worldwide, including over 40 million people in Europe

Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance

Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood

Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA

Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma